Pharmaceutical Executive-10-25-2005

A new meta-analysis confirms the risk of atypical antipsychotics noted by FDA earlier this year. But the reasons for this increased incidence of death remain unclear.

Merck and GSK’s cervical cancer vaccines promise great benefits to women-but there are several key hurdles to clear before the drugs can become the blockbusters the companies are predicting. Analysts debate how long it will take it will take to overcome these obstacles.

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.

A look at the issues facing the Blood Products Advisory Committee when it reviews OraSure’s at-home test next month.